KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Working Capital Changes: 2009-2025

Historic Other Working Capital Changes for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Sep 2025 value amounting to $17.0 million.

  • Biomarin Pharmaceutical's Other Working Capital Changes fell 20.98% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 46.66%. This contributed to the annual value of $3.8 million for FY2024, which is 92.49% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Other Working Capital Changes of $17.0 million as of Q3 2025, which was up 94.33% from $8.8 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Other Working Capital Changes registered a high of $36.0 million during Q1 2023, and its lowest value of -$42.8 million during Q1 2021.
  • Its 3-year average for Other Working Capital Changes is $7.8 million, with a median of $8.8 million in 2025.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first tumbled by 499.78% in 2022, then soared by 349.39% in 2023.
  • Biomarin Pharmaceutical's Other Working Capital Changes (Quarterly) stood at -$2.7 million in 2021, then slumped by 499.78% to -$16.4 million in 2022, then skyrocketed by 44.73% to -$9.1 million in 2023, then slumped by 78.50% to -$16.2 million in 2024, then fell by 20.98% to $17.0 million in 2025.
  • Its last three reported values are $17.0 million in Q3 2025, $8.8 million for Q2 2025, and $6.3 million during Q1 2025.